(2S)-N-[(2-chloro-4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide | 1246278-22-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-[(2-chloro-4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide
• CAS: 1246278-22-7
• 化学式: C₁₂H₁₂ClFN₂O₂
• 分子量: 270.691
• InChiKey: IJYCXCPZIGUWPN-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯-4-氟苄胺 、 L-焦谷氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-N-[(2-chloro-4-fluorophenyl)methyl]-5-oxopyrrolidine-2-carboxamide
  参考文献：
  名称：

  Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor

  摘要：

  A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.033

文献信息

• Discovery and structure–activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor
  作者：Muna H. Abdi、Paul J. Beswick、Andy Billinton、Laura J. Chambers、Andrew Charlton、Sue D. Collins、Katharine L. Collis、David K. Dean、Elena Fonfria、Robert J. Gleave、Clarisse L. Lejeune、David G. Livermore、Stephen J. Medhurst、Anton D. Michel、Andrew P. Moses、Lee Page、Sadhana Patel、Shilina A. Roman、Stefan Senger、Brian Slingsby、Jon G.A. Steadman、Alexander J. Stevens、Daryl S. Walter

  DOI：10.1016/j.bmcl.2010.07.033

  日期：2010.9

  A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies. (C) 2010 Elsevier Ltd. All rights reserved.